SCHEMBL26983763

SCHEMBL26983763

CCP(=O)(CC)c1cc(-c2cccc(N)c2OC)nn1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR8 Q9NR97 2/20 0.35
▸ PARP1 P09874 1/20 0.34
▸ ATM Q13315 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ KDM4E B2RXH2 3/20 0.32
▸ LMNA P02545 1/20 0.32
▸ SCN9A Q15858 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.31
▸ HPGD P15428 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ CA12 O43570 1/20 0.30
▸ CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30051006 1.00 TLR8 (0.35) TLR8PARP1ATMNPC1RAB9A
SCHEMBL30119787 0.86 PARP1 (0.35) TLR8PARP1ATMNPC1RAB9A
SCHEMBL26983719 0.81 PIM1 (0.33) PARP1ATMNPC1RAB9AKDM4E
SCHEMBL30050566 0.81 PIM1 (0.33) PARP1ATMNPC1RAB9AKDM4E
SCHEMBL24783783 0.78 TYK2 (0.33) —
SCHEMBL24782692 0.76 JAK2 (0.48) —
SCHEMBL26983755 0.74 TYK2 (0.40) —
SCHEMBL30780309 0.74 TYK2 (0.40) —
SCHEMBL30780279 0.74 PARP1 (0.31) PARP1
SCHEMBL30968164 0.73 CA12 (0.50) PARP1KDM4ELMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001898-A1 Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof ACCRO BIOSCIENCE HK LTD (HK) 2026-01-01 — — US disclosed
EP-4551559-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF Accro Bioscience (HK) Limited (HK) 2025-05-14 — — EP disclosed
WO-2024010963-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF ACCRO BIOSCIENCE (HK) LIMITED (CN) 2024-01-11 — — WO disclosed
CN-115466289-A Compound with TYK2 inhibitory activity, pharmaceutical composition containing same, and application thereof 爱科诺生物医药(香港)有限公司 2022-12-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001898-A1 Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof JAK1, JAK2, TYK2 TLR8 2853/4885PARP1 2319/4885ATM 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback